Assuntos
Humanos , Masculino , Pré-Escolar , Leucemia Linfoide/terapia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Hospedeiro Imunocomprometido , Coccidiose/diagnóstico , Coccidiose/tratamento farmacológico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Diarreia/parasitologiaRESUMO
The interaction of inhibitory receptors with self-MHC class I (MHC-I) molecules is responsible for NK cell education. The intensity of DNAM-1 expression correlates with NK cell education. However, whether DNAM-1 expression directly influences the functional competence of NK cells via the KIR/MHC-I interaction remains unclear. Based on allogeneic haploidentical hematopoietic stem cell transplantation, we investigated the intensity of DNAM-1 expression on reconstituted NK cells via the interaction of KIR with both donor HLA and recipient HLA at days 30, 90, and 180 after hematopoietic stem cell transplantation. The reconstituted NK cells educated by donor and recipient HLA molecules showed the highest DNAM-1 expression, whereas DNAM-1 expression on educated NK cells with only recipient HLA molecules was higher than that on educated NK cells with only donor HLA molecules, indicating that NK cells with donor or recipient HLA molecules regulate DNAM-1 expression and thereby affect NK cell education. Additionally, the effects of recipient cells on NK cell education were greater than those of donor cells. However, only when the DNAM-1, NKP30, and NKG2D receptors were blocked simultaneously was the function of educated and uneducated NK cells similar. Therefore, activating receptors may collaborate with DNAM-1 to induce educated NK cell hyperresponsiveness. Our data, based on in vitro and in vivo studies, demonstrate that the functional competence of NK cells via the KIR/MHC-I interaction correlates with DNAM-1 expression in human NK cells.
Assuntos
Antígenos de Diferenciação de Linfócitos T/metabolismo , Antígenos de Histocompatibilidade Classe I/imunologia , Células Matadoras Naturais/imunologia , Receptores KIR/imunologia , Antígenos de Diferenciação de Linfócitos T/biossíntese , Estudos de Casos e Controles , Transplante de Células-Tronco Hematopoéticas , Humanos , Leucemia Linfoide/terapia , Leucemia Mieloide/terapia , Síndromes Mielodisplásicas/terapia , Subfamília K de Receptores Semelhantes a Lectina de Células NK/metabolismo , Receptor 3 Desencadeador da Citotoxicidade Natural/metabolismo , Estudos ProspectivosRESUMO
La guía está dirigida al personal clínico asistencial especializado que brinda tratamiento a los pacientes con diagnóstico de LLC, en el contexto del SGSSS colombiano. Incluye a los siguientes profesionales potenciales: Hematólogos y Hematólogos-oncólogos. También está dirigida a los centros asistenciales que brindan cuidado a los pacientes con diagnóstico de LLC y a quienes toman decisiones administrativas, tanto en el medio hospitalario como en las aseguradoras, pagadores del gasto en la salud y en la generación de políticas de salud. Finalmente, las recomendaciones pueden ser de interés para pacientes con LLC, sus familiares y cuidadores. Se considera pertinente aclarar que la guía ofrecerá recomendaciones específicas frente a las preguntas definidas, y excede el alcance de esta, definir las competencias profesionales del equipo involucrado en el manejo de esta patología.
The guide is aimed at specialized clinical care personnel who provide treatment to patients diagnosed with CLL, in the context of the Colombian SGSSS. It includes the following potential professionals: hematologists and hematologist-oncologists. It is also addressed to health care centers that provide care to patients diagnosed with CLL and to administrative decision makers, both in the hospital environment and in the insurance companies, health care payers and health policy makers. Finally, the recommendations may be of interest to CLL patients, their families and caregivers. It is considered pertinent to clarify that the guide will offer specific recommendations in response to the questions defined, and it is beyond the scope of this guide to define the professional competencies of the team involved in the management of this pathology.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Leucemia Linfoide , Leucemia Linfoide/terapia , Programas de Rastreamento , Seleção de Pacientes , Revisão SistemáticaRESUMO
Introducción: La leucemia linfoide crónica es una neoplasia linfoproliferativa crónica caracterizada por el aumento de una población clonal linfoide disfuncional con inmunofenotipo B (> 95 por ciento) y excepcionalmente T (< 5 por ciento) que afecta sobre todo a personas mayores de 55 años de edad y se incrementa su frecuencia hacia la séptima década de vida. Objetivo: Analizar las principales modalidades terapéuticas para el manejo de la leucemia linfoide crónica. Métodos: Se realizó una revisión de la literatura, en inglés y español, a través del sitio web PubMed y el motor de búsqueda Google académico de artículos publicados en los últimos 5 años. Se hizo un análisis y resumen de la bibliografía revisada. Análisis y síntesis de la información: La leucemia linfoide crónica se consideró durante décadas una enfermedad del paciente añoso, en general de curso indolente, con una evolución impredecible e incurable. El tratamiento de esta enfermedad en los últimos 30 años ha sufrido cambios muy significativos que han repercutido favorablemente en el incremento de la supervivencia global y libre de enfermedad de los pacientes que la padecen. Conclusión: Se debe mantener un adecuado seguimiento de los pacientes con leucemia linfoide crónica, pues esto permitirá disminuir en lo posible las complicaciones, la progresión y un aumento de la supervivencia global(AU)
Introduction: Chronic lymphoid leukemia is a chronic lymphoproliferative neoplasm characterized by the increase of a dysfunctional lymphoid clonal population with immunophenotype B (> 95 percent) and exceptionally T (<5 percent), it mainly affects people over 55 years of age, increasing towards the seventh decade of life. Objective: To analyze the main therapeutic modalities for the management of chronic lymphoid leukemia. Methods: A literature review was carried out, in English and Spanish, through the PubMed website and the academic search engine Google for articles published in the last 5 years. An analysis and summary of the revised bibliography was made. Analysis and synthesis of the information: Chronic lymphoid leukemia was considered for decades a disease of the elderly patient, generally of an indolent course, unpredictable and incurable evolution. The treatment of this disease has undergone in the last 30 years very significant changes that have had a favorable impact on the increase in the overall and disease-free survival of patients who suffer from it. Conclusion: Adequate follow-up of patients with chronic lymphoid leukemia must be maintained, as this will make it possible to reduce complications, progression and increase overall survival as much as possible(AU)
Assuntos
Humanos , Pessoa de Meia-Idade , Sobrevida , Leucemia Linfoide/terapia , Assistência ao Convalescente , Intervalo Livre de DoençaRESUMO
Micro RNAs (miRNAs) are a class of small non-coding RNAs that have a crucial role in cellular processes such as differentiation, proliferation, migration, and apoptosis. miRNAs may act as oncogenes or tumor suppressors; therefore, they prevent or promote tumorigenesis, and abnormal expression has been reported in many malignancies. The role of miRNA in leukemia pathogenesis is still emerging, but several studies have suggested using miRNA expression profiles as biomarkers for diagnosis, prognosis, and response to therapy in leukemia. In this review, the role of miRNAs most frequently involved in leukemia pathogenesis is discussed, focusing on the class of circulating miRNAs, consisting of cell-free RNA molecules detected in several body fluids. Circulating miRNAs could represent new potential non-invasive diagnostic and prognostic biomarkers of leukemia that are easy to isolate and characterize. The dysregulation of some miRNAs involved in both myeloid and lymphoid leukemia, such as miR-155, miR-29, let-7, and miR-15a/miR-16-1 clusters is discussed, showing their possible employment as therapeutic targets.
Assuntos
Biomarcadores/sangue , Leucemia Linfoide/sangue , Leucemia Mieloide/sangue , MicroRNAs/sangue , Epigênese Genética , Humanos , Leucemia Linfoide/terapia , Leucemia Mieloide/terapia , Terapia de Alvo Molecular , RNA Circular/metabolismo , RNA Longo não Codificante/metabolismoAssuntos
Biomarcadores Tumorais , Leucemia Linfoide/diagnóstico , Leucemia Linfoide/etiologia , Linfoma/diagnóstico , Linfoma/etiologia , Técnicas de Diagnóstico Molecular/métodos , Tomada de Decisão Clínica , Gerenciamento Clínico , Suscetibilidade a Doenças , Humanos , Leucemia Linfoide/terapia , Linfoma/terapia , Técnicas de Diagnóstico Molecular/normasRESUMO
The ability to change the genetic information of immune cells is a powerful tool for basic and clinical settings. CRISPR/Cas9 gene editing technology by providing an efficient approach has accelerated immune cell therapy of cancers. Lymphoid cancers comprise a wide array of disease including lymphoma, multiple myeloma and lymphocytic leukemia. Here, we review therapeutic applications of the CRISPR/Cas9 technology for immune cell therapy of common lymphoid malignancies. We describe current and future therapeutic application of CRISPR/Cas9 technology with the focus on the production and applications of engineered hematopoietic and immune cells against lymphoid malignancies. Furthermore, we provide an overview of the possible challenges and optimization of CRISPR/Cas9 system for ex- and in vivo applications within recent years.
Assuntos
Proteína 9 Associada à CRISPR/genética , Imunoterapia/métodos , Leucemia Linfoide/terapia , Linfócitos/imunologia , Animais , Sistemas CRISPR-Cas , Edição de Genes , Engenharia Genética , HumanosRESUMO
Recurrent genetic aberrations have long been recognized in mature lymphoid leukemias and lymphomas. As conventional karyotypic and molecular cloning techniques evolved in the 1970s and 1980s, multiple cytogenetic aberrations were identified in lymphomas, often balanced translocations that juxtaposed oncogenes to the immunoglobulin (IG) or T-cell receptor (TR) loci, leading to dysregulation. However, genetic characterization and classification of lymphoma by conventional cytogenetic methods is limited by the infrequent occurrence of recurrent karyotypic abnormalities in many lymphoma subtypes and by the frequent difficulty in growing clinical lymphoma specimens in culture to obtain informative karyotypes. As higher-resolution genomic techniques developed, such as array comparative genomic hybridization and fluorescence in situ hybridization, many recurrent copy number changes were identified in lymphomas, and copy number assessment of interphase cells became part of routine clinical practice for a subset of diseases. Platforms to globally examine mRNA expression led to major insights into the biology of several lymphomas, although these techniques have not gained widespread application in routine clinical settings. With the advent of next-generation sequencing (NGS) techniques in the early 2000s, numerous insights into the genetic landscape of lymphomas were obtained. In contrast to the myeloid malignancies, most common lymphomas exhibit an at least somewhat mutationally complex genome, with few single driver mutations in the majority of patients. However, many recurrently mutated pathways have been identified across lymphoma subtypes, informing targeted therapeutic approaches that are beginning to make meaningful changes in the treatment of lymphoma. In addition to the ability to identify possible therapeutic targets, NGS techniques are highly amenable to the tracking of residual lymphoma following therapy, because of the presence of unique genetic "fingerprints" in lymphoma cells due to V(D)-J recombination at the antigen receptor loci. This review will provide an overview of the impact of novel genetic technologies on lymphoma classification, biology, and therapy.
Assuntos
Leucemia Linfoide/genética , Linfoma/genética , Aberrações Cromossômicas , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Leucemia Linfoide/classificação , Leucemia Linfoide/terapia , Linfoma/classificação , Linfoma/terapia , MutaçãoRESUMO
Signals emanating from the B-cell receptor (BCR) promote proliferation and survival in diverse forms of B-cell lymphoma. Precision medicine strategies targeting the BCR pathway have been generally effective in treating lymphoma, but often fail to produce durable responses in diffuse large B-cell lymphoma (DLBCL), a common and aggressive cancer. New insights into DLBCL biology garnered from genomic analyses and functional proteogenomic studies have identified novel modes of BCR signaling in this disease. Herein, we describe the distinct roles of antigen-dependent and antigen-independent BCR signaling in different subtypes of DLBCL. We highlight mechanisms by which the BCR cooperates with TLR9 and mutant isoforms of MYD88 to drive sustained NF-κB activity in the activated B-cell-like (ABC) subtype of DLBCL. Finally, we discuss progress in detecting and targeting oncogenic BCR signaling to improve the survival of patients with lymphoma.
Assuntos
Leucemia Linfoide/etiologia , Leucemia Linfoide/metabolismo , Linfoma/etiologia , Linfoma/metabolismo , Receptores de Antígenos de Linfócitos B/metabolismo , Transdução de Sinais , Animais , Autoantígenos/imunologia , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/metabolismo , Centro Germinativo/imunologia , Centro Germinativo/metabolismo , Centro Germinativo/patologia , Humanos , Leucemia Linfoide/diagnóstico , Leucemia Linfoide/terapia , Linfoma/diagnóstico , Linfoma/terapia , Receptores de Antígenos de Linfócitos B/genéticaRESUMO
B-cell lymphoblastic lymphoma (B-LBL) is a malignant neoplasm of immature B cells that accounts for only 10% of all cases of lymphoblastic lymphoma. Most commonly, B-LBL presents as bony lesions, but in rare cases, the disease manifests cutaneously. We present a case of simultaneous cutaneous and systemic presentation of B-LBL in an otherwise healthy 28-year-old man in which the lymphoblastic infiltrate stained positive for CD79a, Tdt, CD10, and CD20. A diagnosis of cutaneous B-LBL was made, and systemic work-up revealed widespread involvement of the skin, bone, and lymph nodes. Review of all currently described cases of cutaneous B-LBL with or without systemic involvement revealed that the most frequently positive tumor markers were CD79a (92.3%), Tdt (90.6%), and CD10 (83.3%). Systemic involvement of B-LBL was found in nearly half of all cases with cutaneous presentation.
Assuntos
Leucemia Linfoide/diagnóstico , Linfoma de Células B/diagnóstico , Neoplasias Cutâneas/diagnóstico , Adulto , Antígenos CD20/análise , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biomarcadores Tumorais/análise , Biópsia , Antígenos CD79/análise , DNA Nucleotidilexotransferase/antagonistas & inibidores , Fracionamento da Dose de Radiação , Transplante de Células-Tronco Hematopoéticas , Humanos , Imuno-Histoquímica , Leucemia Linfoide/imunologia , Leucemia Linfoide/patologia , Leucemia Linfoide/terapia , Linfoma de Células B/imunologia , Linfoma de Células B/patologia , Linfoma de Células B/terapia , Masculino , Neprilisina/análise , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Resultado do TratamentoRESUMO
BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. CONCLUSION: Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax.
Assuntos
Quilotórax/radioterapia , Quilotórax/terapia , Transtornos Linfoproliferativos/radioterapia , Transtornos Linfoproliferativos/terapia , Idoso , Quilotórax/tratamento farmacológico , Feminino , Humanos , Leucemia Linfoide/tratamento farmacológico , Leucemia Linfoide/radioterapia , Leucemia Linfoide/terapia , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/radioterapia , Linfoma não Hodgkin/terapia , Transtornos Linfoproliferativos/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Ducto Torácico/efeitos dos fármacos , Ducto Torácico/efeitos da radiaçãoRESUMO
Immunotherapy has played an important part in improving the life of patients with lymphoproliferative diseases especially since the addition of rituximab to chemotherapy in the CD20-positive neoplasms in the 1990s. While this field of passive immunotherapy is continuously evolving, several breakthroughs will expand the treatment modalities to include more active immunotherapy. With the approval of immune checkpoint-blocking antibodies for Hodgkin lymphoma and bispecific antibodies for acute lymphoblastic leukemia (ALL), activation of endogenous T cells already plays a role in several lymphoid malignancies. With the approval of cellular therapies with CAR-T cells for ALL and diffuse large B cell lymphoma, the impact of the manipulation of immune responses is taken even further. Vaccines are cellular therapies in the opposite end of the spectrum in terms of side effects, and while the big breakthrough is still to come, the prospect of a very low-toxic immunotherapy which could be applicable also in premalignant states or in frail patients drives a considerable research activity in the area. In this review, we summarize the mechanisms of action and clinical data on trials in the lymphoid neoplasms with chimeric antigen receptor T cells, bispecific antibodies, immune checkpoint-blocking antibodies, and antineoplastic vaccination therapy.
Assuntos
Imunoterapia , Leucemia Linfoide/imunologia , Leucemia Linfoide/terapia , Linfoma/imunologia , Linfoma/terapia , Animais , Anticorpos Biespecíficos/farmacologia , Anticorpos Biespecíficos/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Biomarcadores Tumorais , Vacinas Anticâncer , Humanos , Imunoterapia/métodos , Imunoterapia Adotiva/métodos , Leucemia Linfoide/diagnóstico , Linfoma/diagnóstico , Linfoma/metabolismo , Receptores de Antígenos Quiméricos/genética , Receptores de Antígenos Quiméricos/metabolismo , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo , VacinaçãoRESUMO
Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δD910A/D910A) in the Eµ-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110δ inactivation led to rectal prolapse in mice resembling autoimmune colitis in patients receiving idelalisib. Moreover, we showed that p110δ inactivation in the microenvironment protected against CLL and acute myeloid leukemia. After receiving higher numbers of TCL1 leukemia cells, half of p110δD910A/D910A mice spontaneously recovered from high disease burden and resisted leukemia rechallenge. Despite disease resistance, p110δD910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response, and depletion of CD4+ or CD8+ T cells restored leukemia. Interestingly, p110δD910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance. Reconstitution of p110δD910A/D910A mice with p110δWT/WT Tregs reversed leukemia resistance. Our findings suggest that p110δ inhibitors may have direct antileukemic and indirect immune-activating effects, further supporting that p110δ blockade may have a broader immune-modulatory role in types of leukemia that are not sensitive to p110δ inhibition.
Assuntos
Linfócitos T CD8-Positivos/imunologia , Classe I de Fosfatidilinositol 3-Quinases/imunologia , Tolerância Imunológica , Leucemia Linfoide/imunologia , Mutação de Sentido Incorreto , Neoplasias Experimentais/imunologia , Linfócitos T Reguladores/imunologia , Substituição de Aminoácidos , Animais , Linfócitos T CD8-Positivos/patologia , Classe I de Fosfatidilinositol 3-Quinases/genética , Ativação Enzimática/genética , Ativação Enzimática/imunologia , Leucemia Linfoide/genética , Leucemia Linfoide/patologia , Leucemia Linfoide/terapia , Camundongos , Camundongos Transgênicos , Neoplasias Experimentais/genética , Neoplasias Experimentais/patologia , Neoplasias Experimentais/terapia , Linfócitos T Reguladores/patologiaRESUMO
Natural killer (NK)/T cell lymphoid malignancy comprises extranodal NK/T cell lymphoma (ENKTL) and aggressive NK cell leukemia (ANKL), and the outcomes for advanced or relapsed/refractory ENKTL and ANKL remain poor. Allogeneic stem cell transplantation (SCT) can be used as a frontline consolidation treatment to prevent the relapse of advanced disease or as salvage treatment after chemotherapy for relapsed sensitive disease. We retrospectively analyzed 36 patients (ENKTL, nâ¯=â¯26; ANKL, nâ¯=â¯10) who underwent upfront (nâ¯=â¯19) and salvage allogeneic SCT (nâ¯=â¯17) at 6 hospitals. Patients received myeloablative (nâ¯=â¯25) or reduced-intensity (n =11) conditioning regimens depending on the institute's policy. The median age at the time of allogeneic SCT was 37 years (range, 17 to 62), and more patients with ANKL (8/10) received upfront allogeneic SCT than ENKTL patients (11/26). Disease status before allogeneic SCT, conditioning regimen, and donor source did not differ between upfront and salvage allogeneic SCT groups. Febrile neutropenia (nâ¯=â¯20) and acute graft-versus-host disease (nâ¯=â¯16) were common adverse events. The median overall survival (OS) and progression-free survival (PFS) after allogeneic SCT were 11.8 months and 10.0 months, respectively. Twelve patients died from disease relapse and 12 from nondisease-related causes. Ten deaths occurred within 100 days after allogeneic SCT (10/24); these were mostly related to disease relapse (nâ¯=â¯8). The OS after allogeneic SCT did not differ between ENKTL and ANKL (Pâ¯=â¯.550) or between upfront and salvage SCT (Pâ¯=â¯.862). Complete chimerism was significantly associated with better PFS (P < .001). No significant differences in PFS were observed based on the conditioning regimen or source of stem cells (P > .05). Allogeneic SCT may be beneficial for patients with ENKTL and ANKL given that some patients were able to maintain their remission after allogeneic SCT. However, allogeneic SCT should only be performed in highly selected patients because the risks of disease relapse and nondisease-related mortality remain high.
Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Leucemia Linfoide/terapia , Células T Matadoras Naturais/metabolismo , Terapia de Salvação/métodos , Transplante Homólogo/métodos , Adolescente , Adulto , Feminino , Humanos , Leucemia Linfoide/patologia , Masculino , Pessoa de Meia-Idade , Células T Matadoras Naturais/patologia , Adulto JovemRESUMO
Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL. Overall response rate to frontline therapy was 69%, and 76% of patients subsequently received allogeneic stem cell transplant (ASCT). After a median follow-up of 11 months, median progression-free survival was 15 months and median overall survival was not reached. In conclusion, FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL. FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.
Assuntos
Biomarcadores Tumorais , Rearranjo Gênico , Leucemia Linfoide/genética , Linfoma/genética , Transtornos Mieloproliferativos/genética , Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/genética , Translocação Genética , Adolescente , Adulto , Idoso , Biomarcadores , Criança , Pré-Escolar , Análise Mutacional de DNA , Feminino , Estudos de Associação Genética , Predisposição Genética para Doença , Humanos , Hibridização in Situ Fluorescente , Lactente , Cariótipo , Leucemia Linfoide/diagnóstico , Leucemia Linfoide/mortalidade , Leucemia Linfoide/terapia , Linfoma/diagnóstico , Linfoma/mortalidade , Linfoma/terapia , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/diagnóstico , Transtornos Mieloproliferativos/mortalidade , Transtornos Mieloproliferativos/terapia , Prognóstico , Adulto JovemRESUMO
The role of HLA system in allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcome is unarguable. In this study we investigated association of HLA-A,-B and-DRB1 alleles with overall survival (OS) in 186 patients undergoing allo-HSCT for lymphoid malignancies. Analyses confirmed significantly better OS for HLA-DRB1∗04 carriers compared with non-carriers (pâ¯=â¯0.01). Survival benefit was confined to male patients (in multivariate analyses pâ¯=â¯0.034, hazard ratio 0.35, 95% confidence interval 0.13-0.92), whereas in females no difference was noted (pâ¯=â¯0.82). Furthermore, donor gender also affected outcome and transplantation from female HLA-DRB1∗04 carrier donors resulted in superior survival compared with female non-carrier donors (pâ¯=â¯0.01). Combined analyses including recipient/donor gender and HLA-DRB1∗04 showed that survival of male patients varied significantly according to donor gender and HLA-DRB1∗04 carriership (pâ¯=â¯0.04) with best survival among HLA-DRB1∗04 carriers transplanted from female donors. Of relevance to our results, HLA-DRB1∗04 has been documented as risk allele group for lymphoid malignancies, and studies described a male-specific risk. We believe that our findings provide further supporting evidence for sex-specific alterations secondary to HLA-DRB1∗04 or related genes. Further studies are warranted to evaluate whether in contrast to general favour of male donors HLA-DRB1∗04 carrier patients with lymphoid malignancies could benefit from transplantation from female donors.
Assuntos
Genótipo , Antígenos HLA-A/genética , Antígenos HLA-B/genética , Cadeias HLA-DRB1/genética , Transplante de Células-Tronco Hematopoéticas , Leucemia Linfoide/genética , Linfoma não Hodgkin/genética , Adulto , Estudos de Coortes , Frequência do Gene , Predisposição Genética para Doença , Teste de Histocompatibilidade , Humanos , Hungria , Leucemia Linfoide/mortalidade , Leucemia Linfoide/terapia , Linfoma não Hodgkin/mortalidade , Linfoma não Hodgkin/terapia , Polimorfismo Genético , Prognóstico , Estudos Retrospectivos , Fatores Sexuais , Transplante Homólogo , Resultado do TratamentoRESUMO
OBJECTIVES: To investigate the dynamic change of follicular T helper cells (TFH) in patients with malignant lymphoid disease (MLD) and to explore its clinical significance. METHODS: The dynamic change of TFH cells, ICOS+- and PD-1+ TFH cells at pretreatment and different treatment periods was determined by flow cytometry in 85 MLD patients. Concentration of interleukin 21 (IL-21) was evaluated by ELISA, and the correlation between clinical prognosis and the ratio of TFH cells was analyzed. RESULTS: Significantly increased ICOS+- and PD-1+ TFH cells were found in MLD patients at pretreatment compared to healthy controls. Decreased or even close to normal levels of ICOS+- and PD-1+ TFH cells were found at the end of treatment. However, in the patients with progressive disease, high levels of ICOS+- and PD-1+ TFH cells were found. Moreover, a significantly increased plasma IL-21 level was found in MLD patients. Negative correlation was found between the level of ICOS+-, PD-1+ TFH cells, as well as IL-21 and the prognosis of MLD. CONCLUSIONS: Significantly increased TFH cell ratios were found in patients with MLD, and decreased TFH cells ratios could be expected in those treatment-effective patients, which could be used as the therapeutic efficacy index.